Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and
one of the comparable parameters of the vaccine response is the determination of IgG …

At the end of 2020, population-based vaccination programs with new generation mRNA-
based vaccines began almost all over the world. The aim of the study was to evaluate the …

Abstract Background The mRNA Covid-19 vaccine (BNT162b2) is administered in two
doses with 21 days interval. On 4th October 2021 European Medicines Agency approved …

Background Mass vaccination is the key element in controlling current COVID-19 pandemic.
Studies comparing immunogenicity of different COVID-19 vaccines are largely lacking. We …

Vaccination against SARS-CoV-2 has become the main method of reducing mortality and
severity of COVID-19. This work aims to study the evolution of the cellular and humoral …

Introduction The necessity of a booster dose is a matter that has not been as yet illuminated,
although it is noted that neutralizing antibody titers decrease over time. We aimed therefore …

Background The humoral immune response after primary immunisation with a SARS-CoV-2
vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an …

Background Since universal vaccinations represents the most effective strategy to mitigate
coronavirus disease 2019 (COVID-19), baseline assessment and post-vaccine monitoring of …

Many available SARS-CoV-2 vaccines demonstrated good humoral response, but studies
directly comparing their immunogenicity in the general population are lacking. We evaluated …

Because the vaccine-elicited antibody and neutralizing activity against spike protein of
SARS-CoV-2 are associated with protection from COVID-19, it is important to determine the …